Peregrine Announces Grant of Patent for New Class of Vascular Targeting Agents

Peregrine and OXiGENE Conclude Arcus Therapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies

Peregrine Pharmaceuticals Announces $2.2 Million Investment From Institutional Investors

Peregrine Pharmaceuticals Announces Grant of Patent for New Anti-Cancer Antibodies

Peregrine Pharmaceuticals Announces Formation of Contract Manufacturing Subsidiary Avid Bioservices Inc.

Peregrine Pharmaceuticals Announces the Initiation of Human Antibody Generation Against Two Additional Antigen Targets With Xenerex Biosciences

Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Similar Characteristics of Chimeric and Human TNT Monoclonal Antibodies

Peregrine Announces Quarterly Conference Call

Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme

Peregrine Pharmaceuticals Announces $5.75 Million Investment From Institutional Investors; Company Director Invests in Offering